Background Surgical indications for liver hemangioma remain unclear. Methods Of 510 patients undergoing surgical resection for liver hemangioma in 118 Japanese centers between 1998 and 2012, abdominal symptoms, diagnostic accuracy, and surgical outcomes were analyzed to propose size-based surgical indications. Patients were classified into four groups based on tumor size: Group A ≤5 cm (n = 122, 24%), Group B 5-10 cm (n = 164, 32%), Group C 10-15 cm (n = 124, 24%), and Group D >15 cm (n = 100, 20%). Results Hemangiomas in Group A were most frequently diagnosed as malignant tumors (43.5%) due to the absence of typical imaging findings and with highest incidence of positive HBV (15.7%). Diagnostic accuracy was 98.4% in Groups B to D. Liver failure after hepatectomy was higher in Group D than in Groups A to C (3.0% vs. 0.5%, P = 0.02). Only one operative death was observed (0.2%) in Group D. Conclusions In patients with ≤5 cm hemangioma, surgical resection can be indicated when a malignant tumor cannot be ruled out. However, surgery for 5-10 cm asymptomatic hemangiomas should be limited. Experienced hepatic surgeons should conduct hepatectomy for tumors >15 cm to avoid serious morbidity or mortality.
Introduction
Liver hemangioma is one the most common benign liver neoplasms, affecting 3-20% of the general population [1] [2] [3] . Although majority of the patients with hemangiomas are diagnosed incidentally and are asymptomatic, abdominal symptoms and the incidence of the coagulation disorder known as Kasabach-Merritt syndrome increases proportionally with the tumor size; however, there has been no evidence-based consensus or guidelines describing surgical indications for liver hemangiomas. While prophylactic hepAs for surgical indications for liver hemangioma, tumor size is the clearest and most frequently used criterion. Giant hemangioma is defined as cavernous hemangioma >10 cm in size [11] or >20 cm in size [12] : liver resection is indicated for symptomatic giant hemangiomas. Others advocated that surgical resection should be considered for symptomatic hemangiomas irrespective of tumor size [13] . Therefore, surgical indication for liver hemangioma is best determined by both tumor size and/or clinical symptoms.
The objective of this study was to conduct a nationwide survey on resected cases of liver hemangioma and propose size-based surgical indication criteria for this disease (Research project 05 of Japanese Society of HepatoBiliary-Pancreatic Surgery).
Methods
Among the 213 institutions for board certified surgeons of the Japanese Society of Hepato-Biliary-Pancreatic Surgery, 126 institutions (59%) participated in this study conducted in 2014. The clinicopathological data of 566 patients who had undergone hepatectomy for hepatic hemangioma between 1998 and 2012 were collected from 118 institutions listed at the end of the manuscript. Hepatic hemangioma was diagnosed at each institution based on imaging studies, clinical data, and histological analyses. Histopathological diagnoses included cavernous hemangioma (n = 534 patients), angiomyolipoma (n = 15), sclerosing hemangioma (n = 14), and others (n = 3). The clinicopathological data of the 534 patients with cavernous hemangioma were examined to explore the proper surgical indication for this entity. Of these, there were 163 men and 365 women, with a median age of 51.0 years (24-83 years). Hepatitis B virus was positive in 24 patients (4.6%), and hepatitis C virus was positive in 31 patients (6.0%). The background liver was normal in 475 patients (89.0%), but the rest of the patients had chronic hepatitis (n = 42, 7.9%), steatosis (n = 9, 1.7%), cirrhosis (n = 3, 0.6%) and others (n = 5, 0.9%). As subgrouping of the entire cohort was done based on the tumor size before hepatectomy, 510 patients out of 534 were the subjects of the following study.
Approval to perform this retrospective study was obtained first in The University of Tokyo (Review number: 10300) and then in each of the institutional review boards; consents from the study participants were waived.
Subgrouping the subjects based on the tumor size The entire cohort of 510 patients with liver hemangioma was classified into four groups based on the tumor size observed on the imaging findings at the time of surgery: Group A ≤5 cm (n = 122, 24%), Group B >5 cm and ≤10 cm (n = 164, 32%), Group C >10 cm and ≤15 cm (n = 124, 24%), and Group D >15 cm (n = 100, 20%).
Preoperative data included the background of patients, abdominal symptoms, the presence of coagulopathy including Kasabach-Merritt syndrome, signs of tumor rupture, the follow-up period and increase in tumor size, the imaging findings on abdominal ultrasonography (US), computed tomography (CT) scan, magnetic resonance imaging (MRI), and angiography. Kasabach-Merritt syndrome was defined as decreased platelet count and consumption coagulopathy with/without disseminated intravascular coagulation in patients with cavernous hemangioma. The judgment of the presence of this syndrome was left to each institution. Imaging findings were focused on the typical findings of cavernous hemangioma, that is, (1) hyper-echogenicity on US, (2) early and late enhancement on dynamic CT or MRI, (3) high-intensity on MRI T2-weighed image, and (4) cotton wool appearance on angiography. Operative factors included the method of surgical approach, surgical curability, and postoperative morbidity and mortality. The detail of criteria for postoperative bleeding [14] , bile leakage [15] , liver failure [16] , and other complications defined by Clavien-Dindo [17] are listed in Appendix S1.
Statistical analysis
Relationships between categorical variables were tested using v 2 analysis, and continuous data were analyzed using the Mann-Whitney U-test. Survival curves for overall survival were generated using the Kaplan-Meier method and compared using the log-rank test. To identify risk factors for death, multivariate regression analysis was performed with the Cox proportional hazards model using a backward elimination procedure. Probability (P) values <0.05 were considered statistically significant. Data were analyzed using the SPSS version 19.0 software program (SPSS, Chicago, IL, USA).
Results
Background characteristics of 510 patients undergoing hepatectomy for hemangioma
The incidence of HBV positive in Group A was 15.7%, which was significantly higher than the remaining three groups, while the incidence of HCV was slightly higher in Group A (6.6%). No significant difference was found in the hepatic function among the four groups ( Table 1) .
Difference of imaging findings of hemangioma based on tumor size
The diagnostic key findings for liver hemangioma were compared according to the size of the tumor between Group A (≤5 cm) and Groups B to D (>5 cm) ( Table 1) . No significant difference in hyper-echogenicity on ultrasonography was found between the two groups. However, early and late enhancement on dynamic CT or MRI, highintensity on MRI T2-weighed image and cotton wool appearance on angiography were more frequently found in tumors >5 cm than in tumors ≤5 cm, which suggested that ≤5 cm hemangioma was associated with more frequent atypical findings as cavernous hemangioma.
Accuracy of preoperative diagnosis
Accuracy of preoperative diagnosis was significantly lower in Group A than in Groups B to D (46.6% vs. 98.4%, P < 0.001). In Group A, the differential diagnoses included hepatocellular carcinoma in 20.1%, liver metastasis in 20.1%, intrahepatic cholangiocarcinoma in 3.3% and others in 10% of patients.
Symptoms associated with hemangioma
The incidence of abdominal pain and distension rose in proportion with the tumor size, and in Group D, 55% of patients complained of abdominal distension (Fig. 1) . The overall incidence of Kasabach-Merritt syndrome was 8.3% (42 out of 509 patients). This syndrome was more frequently found as the tumor size increased. The platelet counts, fibrinogen, and prothrombin times decreased, while D-dimer increased in proportion with the tumor size ( Table 1) . Tumor rupture was suspected preoperatively in 2.4% (12 out of 509 patients) and it was significantly higher in Group D than in Groups A to C (5.0% vs. 1.7%, P = 0.049); however, tumor rupture was confirmed intraoperatively only in 1.4% (seven out of 510 patients). Table 1 Background characteristics and laboratory data of 510 patients undergoing hepatectomy for hemangioma classified into four groups by the tumor size ns not significant The incidence of actual rupture was higher in tumors ≥10 cm than tumors <10 cm (2.7% vs. 0%, P = 0.01), and it was 2.0% (two out of 100 patients) in Group D.
On the other hand, the percentage of patients without any sign of abdominal pain, abdominal distension, Kasabach-Merritt syndrome, or suspicious of tumor rupture was 85%, 71%, 46%, and 27% in Groups A, B, C and D, respectively. Patients without the above symptoms and with preoperative diagnoses of hemangioma were 34%, 69%, 46%, and 25%, in Groups A, B, C and D, respectively (47% in total), which may be candidates for careful observation.
Waiting period before hepatectomy and tumor growth
The waiting period before hepatectomy was significantly longer in Group D than in Groups A to C (12 months vs. 3 months, P < 0.001), and it was significantly shorter in Group A than in tumors >5 cm (2.0 months vs. 6 months, P < 0.001) (Fig. 2a) . The tumor size increased significantly during the waiting period in each of the four groups (Fig. 2b) ; however, the median ratio of tumor size before hepatectomy to tumor size at initial diagnosis was Hepatectomy for hemangioma and surgical morbidities Table 2 shows the surgical parameters associated with hepatectomy. Preoperative transcatheter arterial embolization (TAE) was done more frequently in patients with ruptured hemangioma than in those with non-ruptured hemangioma before hepatectomy (28.6% vs. 5.9%, P = 0.01). The laparoscopic approach was adopted in 26%, 24%, 11%, and 0% of patients in Groups A, B, C and D, respectively. Complete resection was accomplished in 94%, 89%, 83%, and 78% of patients in Groups A, B, C and D, respectively.
As the tumor size increased, more extensive hepatectomies were required (Fig. 3a) , the operative time was longer (Fig. 3b) , the blood loss was larger (Fig. 3c) , and the blood transfusions were more frequently (Fig. 3d) . Table 3 summarizes overall surgical morbidity and mortality. One patient died due to septic complications (0.2%). Clinically significant morbidity, that is, grade B or C morbidities are shown in Figure 4 . No significant difference was observed in the incidence of postoperative bleeding in any of the groups or in any of the cut-off sizes. Bile leakage was higher in tumors >10 cm (Groups C and D) than in tumors (Groups A and B) <10 cm (5.4% vs. 0.3%, P < 0.001). Liver failure was higher in tumors ≥15 cm (Group D) than in tumors <15 cm (Groups A to C) (3.0% vs. 0.5%, P = 0.02). Surgical morbidities other than the above three major morbidities more severe than Clavien-Dindo III were found in 18 patients. Of these, 13 patients required pleural effusion drainage. These morbidities were found more frequently in Group D than in Groups A to C (11% vs. 1.7%, P < 0.001).
Improvement of symptoms and long-term survival after hepatectomy Improvement of symptoms was confirmed in 44%, 64%, 83%, and 87% of patients in Groups A, B, C and D, respectively. The rate of improvement was higher in 
Discussion
This nationwide survey revealed the current status of surgical treatment for liver hemangioma in Japan. In this study, 566 patients were enrolled and the data of 510 patients suffering from liver hemangioma were analyzed with special emphasis on the tumor size and clinical symptoms. The number of enrolled patients (n = 556) was significantly higher than that ever reported (n = 241) [9] . It is sometimes difficult to precisely diagnose hemangiomas ≤5 cm in diameter, because they sometimes do not show typical imaging findings as cavernous hemangiomas, especially in patients with hepatitis virus (Table 1) . Therefore, surgical resection for hemangiomas ≤5 cm was done on suspicion of malignancy in 43.5%. On the other hand, preoperative diagnosis of liver hemangioma was easy and reliable when the tumor size was >5 cm. In Group B, more than twothirds of patients turned out to be suitable for careful observation; this revealed the excessive surgical indication for liver hemangioma in this nationwide survey. Hemangiomas >10 cm with clinical symptoms would be possible indication for surgery, however, hepatectomy, indicated for tumor sizes >15 cm, was associated with considerable risks of liver failure (Grade B/C, 3%) or other surgical complications (11%). Thus, hepatectomy for large hemangiomas should be done in high-volume centers by experienced liver surgeons.
It has been reported that the best imaging method for cavernous hemangioma is MRI, as its sensitivity and specificity are 85-95% [18] . The most specific features are bright signal intensity on T2-weighted images and a slow centripetal pattern of peripheral enhancement after administration of gadolinium-based contrast material. A characteristic peripheral nodular enhancement occurs during the arterial phase, with subsequent progressive centripetal enhancement on portal venous phase images. This specific pattern occurred in 94% of giant hemangiomas [19, 20] . On delayed phase, the pattern appears isodense or hyperdense as compared to liver parenchyma; however, in this study, these typical imaging findings for cavernous hemangioma were significantly less in Group A than in Groups B to D (Table S1) ; moreover, the accuracy of preoperative diagnosis was lower in Group A than in Groups B to D (46.6% vs. 98.4%, P < 0.001). These results suggest that it is sometimes difficult to diagnose hemangioma ≤5 cm, and one cannot avoid hepatectomy for asymptomatic hemangiomas with suspicious of malignancy.
Symptoms for hemangioma include abdominal pain, distension, rupture, and coagulopathy disorders. It has been reported that abdominal discomfort was found in 66.3% of 86 patients with a hemangioma >10 cm [11] . In this study, abdominal distension was the most frequent clinical presentation, and the incidence of abdominal distension was higher in tumors >10 cm than in tumors ≤10 cm (43.0% vs. 9.8%, P < 0.001). On the other hand, spontaneous rupture of a hemangioma is to be considered as an exceptional event [8] . Traumatic rupture or hemorrhage was found in three out of 241 patients (1.2%) in a multi-institutional analysis in the USA [9] . A MEDLINE search of articles published between 1898 and 2010 found 97 cases of ruptured hemangioma [8] . Of these, 46 patients (47%) developed spontaneous rupture, and the remaining 53% developed secondary rupture, which occurred during pregnancy, after delivery or in patients receiving anticoagulation therapy. In this review, the mean size of the ruptured lesions was 11.2 cm, but the size was not a significant risk factor for rupture. In cases of rupture, massive bleeding occurred in 90% of patients, and the mortality rate in the past 20 years has significantly decreased from before (3.2% = 1/32 vs. 50% = 33/66, P < 0.001) [8] . In this series, the incidence of hepatectomy for ruptured hemangioma was only 1.4%, and all of TAE transcatheter arterial embolization the ruptured hemangiomas measured ≥10 cm. Surgical resection for ruptured hemangioma can be safely done in combination with TAE and hepatectomy nowadays. Therefore, prophylactic hepatectomy for hemangioma to prevent tumor rupture in the future cannot be justified even in tumors >10 cm. Our data also showed that 46% of 10-15 cm hemangioma had no clinical symptoms and could be candidates for careful observation. Details of coagulopathy disorders associated with hepatic cavernous hemangioma have not been thoroughly investigated. In the USA, Kasabach-Merritt syndrome was found in one of 241 patients (0.3%) in a multi-institutional analysis [9] ; however, it was found in 26% of tumors >15 cm in the present study. Even without the diagnosis of Kasabach-Merritt syndrome, laboratory parameters suggesting coagulopathy disorder increase in proportion as tumor size increased (Table 1) . Clinically problematic cut-off criteria for these parameters should be further elucidated.
The greater the tumor size, a more extensive hepatectomy was required. In a multi-institutional analysis in the USA, the incidence of bile leak, bleeding, liver failure and surgical mortality was 3.4%, 2.2%, 0%, and 0%, respectively, in 241 patients who had undergone hepatectomy [9] . These morbidity rates were comparable with those presented in this study. With a liver failure incidence of 3.0% in Group D, and the potential of liver failure leading to surgical death, it can be recommended that surgical resection for tumors >15 cm should be performed in high-volume centers by experienced hepatic surgeons. After hepatectomy, the proportion of patients whose symptoms improved was greater in those who had larger tumors. In Groups C and D, more than 80% of patients experienced improvement of the clinical symptoms. In a multi-institutional analysis in the USA, the symptoms were improved in 129 out of 241 patients (63.2%) [9] . It is important to exclude extraneous causes of symptoms before surgery [11] . Symptoms persist after hepatectomy probably because of another undiagnosed problem, such as irritable bowel disease, peptic ulcer or reflux disease [13, 21] .
The natural history of hemangiomas is not well-known, and the rational for prophylactic surgery before tumor overgrowth or rupture is still controversial. Yedibela et al. reported a comparative study of patients with hemangioma between observation (n = 143) and surgery (n = 103) [10] . In the observation group, 56% of patients had persistent or new onset of hemangioma associated symptoms. Major complications associated with hemangioma occurred in 12 patients (9%) during the follow-up; however, two patients died after traumatic rupture. In this study, the waiting period before hepatectomy was 2-12 months, but the median ratio of the tumor size at initial diagnosis to the size before hepatectomy was 1.0 in all Groups, which suggested that the tumor size will not increase so much with an interval of 1 year in general. Rapid increase in tumor size would be a relative indication for hepatectomy to decrease the surgical risks of hepatectomy and eliminate patient anxiety.
In a multicenter analysis in the USA, 241 patients who underwent resection for hemangioma with a median size of 8.5 cm, surgery was indicated for abdominal symptoms (85%), and increasing size (11%), and patient anxiety (4%). The authors advocated that resection of hemangioma should be performed in high-volume institutions in patients with intractable symptoms [9] . They also insisted that prophylactic resection in asymptomatic patients solely for size or enlargement is not adequate, because no severe complications are associated with observation. After reviewing the present nationwide survey, we suggest that the current surgical indications may be excessive, because 47% of patients with hemangioma underwent hepatectomy without any symptoms and with typical imaging findings such as cavernous hemangioma in the present study. Prophylactic hepatectomy for anxiety or to prevent future rupture cannot be recommended, because it is not too late to safely treat ruptured hemangiomas in the present 21 st century.
The retrospective study design and inclusion of only surgical patients with liver hemangioma undergoing hepatectomy are the major drawbacks of this study. We cannot deliberate the advantages and disadvantages of observation for asymptomatic liver hemangiomas; however, in Group D, the median duration between initial diagnosis and hepatectomy was 1 year, and the median size of hemangioma did not change during the period. In addition, the incidence of hemangioma rupture in Group D was 2% even in the large ones. These facts strongly suggest that asymptomatic hemangiomas can be observed safely.
Conclusion
In patients with ≤5 cm hemangioma, surgical resection can be justified for tumors with suspicion of malignancy.
In patients with 5-10 cm asymptomatic hemangioma, diagnostic accuracy of preoperative diagnosis is high; therefore, surgical resection will be unnecessary in asymptomatic patients. Tumor measuring >10 cm would be candidates for surgery in patients with abdominal symptoms or coagulopathy. For tumors >15 cm, hepatectomy should be performed in high-volume centers by experienced hepatic surgeons to avoid serious morbidity.
